Skip to main content


The Center for Vaccine Development and Global Health (CVD) is conducting a research study to investigate the use of the FDA-approved mpox vaccine for an adolescent population.

The study will compare the safety and immune response of adolescents who receive the licensed dose of JYNNEOS with that of adults who receive JYNNEOS. The study data will be used to support the FDA's approval of JYNNEOS for use in adolescents. However, JYNNEOS is currently not approved by the FDA for use in adolescents, and this vaccine is still in the investigational stage.

JYNNEOS has already been administered to children, adolescents, and adults who were exposed to mpox, including those who were at a higher risk of contracting mpox during the 2022 mpox outbreak. JYNNEOS is currently the only FDA-approved vaccine for mpox and is the preferred choice. Nonetheless, it is not approved for non-emergency use in adolescents.

•    Participation in this study will last about 13 months. 
•    You will be compensated up to $1000 for completed study visits.
•    You must be 12-17 years old to participate.

Ready to get started?

Call: 410-706-8800 (8am-4pm)

Learn More

Back to All Studies